Erasca initiates global Phase 3 SEACRAFT-2 trial for naporafenib + trametinib in NRAS-mutant melanoma

Erasca, Inc.

SEACRAFT-2 evaluates pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib vs trametinib alone.
Stage 1 of the Phase 3 trial is expected to yield a randomized data readout in 2025.
Trial targets NRAS-mutant melanoma, a setting with limited approved targeted therapies.
Initiation marks the first Phase 3 trial for Erasca's wholly owned candidate naporafenib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.